Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial

[1]  B. Christian,et al.  Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. , 1998, Journal of cardiovascular pharmacology.

[2]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[3]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[4]  E. Braunwald,et al.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.

[5]  C. Bauters,et al.  Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. , 1998, Circulation.

[6]  Gebhardt,et al.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina , 1998 .

[7]  B. Sobel,et al.  Unexpected, Discordant Effects of Aspirin on Platelet Reactivity , 1998 .

[8]  E. Antman,et al.  Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trials , 1998 .

[9]  M. Owings,et al.  1995 summary: National Hospital Discharge Survey. , 1997, Advance data.

[10]  U. Losert,et al.  Variable Platelet Response to Low-dose ASA and the Risk of Limb Deterioration in Patients Submitted to Peripheral Arterial Angioplasty , 1997, Thrombosis and Haemostasis.

[11]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[12]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[13]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[14]  I. Palacios,et al.  Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. , 1997, Circulation.

[15]  R. Califf,et al.  Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. , 1997, Circulation.

[16]  P. Théroux,et al.  Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. , 1996, Circulation.

[17]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[18]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[19]  E. Topol,et al.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.

[20]  S. Brister,et al.  Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. , 1995, The Canadian journal of cardiology.

[21]  D. Ardissino,et al.  Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction , 1994, Circulation.

[22]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[23]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[24]  K. Grotemeyer,et al.  Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. , 1993, Thrombosis research.

[25]  R. Califf,et al.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. , 1993, Journal of the American College of Cardiology.

[26]  P. Roderick,et al.  The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. , 1993, British journal of clinical pharmacology.

[27]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[28]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[29]  D. Brahams.  AIDS in the United States: Education and Litigation , 1988, The Lancet.

[30]  C. Hennekens,et al.  A randomized trial of aspirin and β-carotene among U.S. physicians , 1985 .

[31]  J. O'brien,et al.  Effects of salicylates on human platelets. , 1968, Lancet.

[32]  L. Aledort,et al.  Impaired platelet-connective-tissue reaction in man after aspirin ingestion. , 1967, Lancet.